Discover how quality-driven drug development and AI accelerate safer medicines, reduce risk, and improve patient outcomes.

The S&P SmallCap 600 underperformed the Russell 2000 by 9% YTD, putting it on track to record its worst year of relative performance since its launch in October 1994. The S&P SmallCap 600’s relative ...

This first systematic review on Quality by Design (QbD) in nanocosmetics analyzed 52 original articles, identifying particle size (94.2%), polydispersity index (76.9%), and zeta potential (75%) as the ...

The S&P SmallCap 600 represents the U.S. small-cap equity market by tracking companies that meet specific liquidity and financial viability criteria. While both the S&P 600 and Russell 2000 target ...